ClinicalTrials.gg
Not yet recruitingNCT07867171Updated Oct 9, 2026

A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib

A Phase 1 interventional study of Velzatinib in Healthy Participants and Gastrointestinal Neoplasms, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Oct 9, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study evaluates the effect of moderate and severe renal impairment on the pharmacokinetics (PK) of velzatinib compared with normal renal function.

02

Conditions studied

  • Healthy Participants
  • Gastrointestinal Neoplasms

Keywords

  • Healthy participants
  • Renal Impairment
  • Pharmacokinetics
  • Velzatinib
03

In context

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

This study's planned enrollment of 30 is below the median of 74 across 495 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are 18 to 80 years of age, inclusive, at the time of signing the form (ICF).
  • Participants has stable renal function that can be classified into 1 of 3 groups based on estimated at screening.
  • Participants with moderate/severe RI may be taking medications, which in the opinion of the investigator, are believed to be therapeutic but do not affect study drug Absorption, distribution, metabolism, excretion (ADME).
  • The participant has no and unstable cardiovascular (CV) or endocrine findings, except as expected by their pre-existing renal condition in the investigator's opinion (participants with renal impairment).
  • Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. Participants with chronic disorders such as hypertension and diabetes mellitus can be enrolled, provided those disorders are stable and adequately controlled, but otherwise participants should be considered healthy for their age (participants with normal renal function).

Exclusion criteria

Exclusion Criteria:

  • Participants has a history or evidence of hematologic, dermatologic, neurologic, pulmonary, immunologic or atopic (except seasonal allergies), or endocrine disease, or psychiatric disorder (such as psychosis, delusions, or schizophrenia), or other abnormality, that may impact the ability of the participant to participate or potentially confound the study results, or that, in the investigator's opinion, makes the participant unsuitable for the study.
  • Semi-supine blood pressure (BP) outside the ranges of 100 to 160 millimeters of mercury (mmHg) for systolic BP and 50 to 95 mmHg for diastolic BP (BP to be measured in triplicate), or a semi-supine pulse rate outside the range of 45 to 100 beats per minute (bpm).
  • Participants has orthostatic hypotension such that there is a decrease in systolic BP of greater than equal to (>=)20 mmHg or in diastolic BP of >=10 mmHg, or pulse rate increase >=30 bpm.
  • Has current or chronic history of liver disease (including acute or chronic or ) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) (participants with renal impairment).
  • Has nephrotic syndrome.
  • Has a clinically significant elevation in serum potassium, that in the opinion of the investigator and medical monitor will interfere with the study or introduce additional safety risk to the participant.
  • Has a serum sodium level \<=125 milliequivalents per Liters (mEq/L) (participants with renal impairment).
  • Has a functioning, likely or planned renal transplant (participants with renal impairment).
  • On dialysis or considered likely to require dialysis during the study (participants with renal impairment).
  • Has clinically significant cardiac disease, including second- or third-degree atrioventricular block, clinically significant tachyarrhythmias, or atrial fibrillation/flutter.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Participants with Moderate Renal Impairment receiving velzatinib

    Drug: Velzatinib

  • Experimental
    Participants with Severe Renal Impairment receiving velzatinib

    Drug: Velzatinib

  • Active comparator
    Participants with Normal Renal Function receiving velzatinib

    Drug: Velzatinib

Interventions

  • Velzatinib will be administered.

    Also known as: GSK6042981/IDRX-42

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 936 hours

  2. Area under the concentration-time curve from time zero extrapolated to infinity (AUC[0-inf])

    Time frame: Up to 936 hours

  3. Maximum plasma unbound concentration (Cmax,u)

    Time frame: Up to 936 hours

  4. Area under the unbound plasma concentration-time curve extrapolated to infinity (AUC[0-inf],u)

    Time frame: Up to 936 hours

  5. Renal clearance (CLr)

    Time frame: Up to Day 3

Secondary outcomes

  1. Time to maximum observed plasma concentration (Tmax)

    Time frame: Up to 936 hours

  2. Area under the concentration-time curve from time zero to 48 hours post-dose administration (AUC[0-48])

    Time frame: Up to 48 hours

  3. Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-last])

    Time frame: Up to 936 hours

  4. Terminal elimination rate constant

    Time frame: Up to 936 hours

  5. Apparent terminal phase half-life (t1/2)

    Time frame: Up to 936 hours

  6. Apparent clearance (CL/F)

    Time frame: Up to 936 hours

  7. Apparent volume of distribution (Vz/F)

    Time frame: Up to 936 hours

  8. Total amount of drug excreted into urine

    Time frame: Up to Day 3

  9. Percentage of the total dose of drug excreted into urine

    Time frame: Up to Day 3

  10. Regression coefficient between pharmacokinetic parameters and measures of renal function

    The relationship between PK parameters and measures of renal function will be evaluated using regression analyses. Regression coefficients will be summarized to describe the direction and magnitude of the relationship. A positive regression coefficient indicates that an increase in the renal function parameter is associated with an increase in the PK parameter, whereas a negative regression coefficient indicates that an increase in the renal function parameter is associated with a decrease in the PK parameter. A regression coefficient close to zero suggests little or no linear relationship between the renal-function measure and the PK parameter. Unit of measure: unitless (will be reported as a regression coefficient).

    Time frame: Up to 936 hours

  11. Number of participants with adverse event (AEs) and serious adverse event (SAEs) by severity

    Time frame: Up to Day 40

  12. Number of participants with clinically important changes in vital signs, electrocardiograms (ECG), physical examination and clinical laboratory parameters

    Time frame: Up to Day 40

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 10 months later.

Of 50 phase 1 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 71. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 9, 2026
StartEst.
Oct 23, 2026
Primary completionEst.
Sep 9, 2027
CompletionEst.
Sep 9, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867171
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 23, 2026 (estimated)
Primary completion
Sep 9, 2027 (estimated)
Completion
Sep 9, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDRX-42

Start the discussion